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Maria Yazdanbakhsh, PhDb Accra, Ghana, Leiden and Amsterdam, The Netherlands, Uppsala, Sweden, and Madrid, SpainBackground: The prevalence of peanut allergy has increased in
developed countries, but little is known about developing
countries with high peanut consumption and widespread
parasitic infections.
Objective: We sought to investigate peanut allergy in Ghana.
Methods: In a cross-sectional survey among Ghanaian
schoolchildren (n 5 1604), data were collected on reported
adverse reactions to peanut, peanut sensitization (serum specific
IgE and skin reactivity), consumption patterns, and parasitic
infections. In a subset (n5 43) IgE against Ara h 1, 2, 3, and 9 as
well as cross-reactive carbohydrate determinants (CCDs) was
measured by using ImmunoCAP. Cross-reactivity and biological
activity were investigated by means of ImmunoCAP inhibition
and basophil histamine release, respectively.
Results: Adverse reactions to peanut were reported in 1.5%,
skin prick test reactivity in 2.0%, and IgE sensitization (>_0.35
kU/L) in 17.5% of participants. Moreover, 92.4% of those IgE
sensitized to peanut (>_0.35 kU/L) had negative peanut skin prick
test responses. Schistosoma haematobium infection was
positively associated with IgE sensitization (adjusted odds ratio,
2.29; 95% CI, 1.37-3.86). In the subset IgE titers to Ara h 1, 2, 3,
and 9 were low (<1.3 kU/L), except for 6 moderately strong
reactions to Ara h 9. IgE against peanut was strongly correlated
with IgE against CCDs (r 5 0.89, P < .0001) and could be almost
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Open access under CC BY-NC-ND license.egg antigen. Moreover, IgE to peanut showed poor biological
activity.
Conclusions: Parasite-induced IgE against CCDs might account
largely for high IgE levels to peanut in our study population of
Ghanaian schoolchildren. No evidence of IgE-mediated peanut
allergy was found. (J Allergy Clin Immunol 2013;132:639-47.)
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Recent studies report a significant increase in the incidence of
peanut allergy, particularly in Europe and North America, where
self-reported peanut allergy is approximately 1% among subjects
less than 18 years of age.1,2 According to a 5-year follow-up sur-
vey among children in Montreal, Canada, peanut allergy preva-
lence (confirmed by skin prick tests [SPTs] and oral food
challenges) increased from 1.34% in 2000-2002 to 1.62% in
2005-2007,3 and a population-based study conducted in Australia
among infants aged 12months found the prevalence of challenge-
proved peanut allergy to be 3.0%.4
Although extensive peanut allergy research has been conducted
in Western countries, there are only a few published studies from
other areas of the world where peanut consumption is high, such
as Southeast Asia. A population-based questionnaire survey in
children of both 4 to 6 years and 14 to 16 years of age in 2 Asian
populations indicates that self-reported adverse reactions to
peanut in this region might vary between 0.43% and 0.64%.5 Ad-
ditionally, a food allergy study among children 6 to 11 years old in
China, India, and Russia described peanut allergy to be uncom-
mon in all 3 countries.6 For Sub-Saharan Africa, no published
data are available to date.
One reason proposed to explain the lower prevalence of allergic
disorders in many developing countries is the possible suppres-
sive role of chronic infections on the development of allergies.7
Infections, especially parasitic ones, are highly prevalent in
Africa, Asia, and South America, particularly in rural areas or
in poor sections of urban communities.8-10 One mechanism by
which helminth infections are believed to protect against allergies
is by activating regulatory networks that involve the induction of
regulatory T and B cells, as well as the modulation of innate im-
mune cells.11,12 Another mechanism of recent interest has been
how cross-reactivity between parasite/helminth antigens and al-
lergens can affect IgE sensitization patterns and their translation
into clinical symptoms.13,14
Because there is little information on peanut allergy in Sub-
Saharan Africa and on associated risk factors, we set out to
investigate the epidemiology of peanut allergy in schoolchildren639
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640 AMOAH ET ALAbbreviations usedaOR: Adjusted odds ratioBHR: Basophil histamine releaseCCD: Cross-reactive carbohydrate determinantCRD: Component-resolved diagnosticsSEA: Soluble egg antigenSPT: Skin prick testin Ghana, a country where peanut consumption is estimated to be
high. In 2009 alone, the per capita consumption of peanuts in
Ghana was approximately 12 kg15 compared with a per capita
estimate of 6.6 kg for the United States in the same year.16 Our
objective was to identify factors associated with peanut sensitiza-
tion and reported symptoms, such as parasitic infections, peanut
consumption patterns, and peanut preparation methods. We also
sought to characterize IgE reactivity to peanut in our population.METHODS
Study design and population
We conducted a cross-sectional study between March 2006 and March
2008 that was part of a larger investigation into allergic sensitization and
parasitic infections in schoolchildren in Southern Ghana. This investigation
was carried out within the framework of the European Union–funded
EuroPrevall17 and GLOFAL18 projects (see details in the Methods section in
this article’s Online Repository at www.jacionline.org). Outcome parameters
of interest were (1) reported adverse reactions to peanut and (2) peanut sensi-
tization based on serum specific IgE levels and SPT reactivity. The study was
approved by the Noguchi Memorial Institute for Medical Research Institu-
tional Review Board, Ghana (NMIMR-IRB CPN 012/04-05). Three districts
in the Greater Accra Region were selected for the investigation. Within these
districts, schools were randomly selected and approached to participate in the
study (see sampling methodology in the Methods section in this article’s
Online Repository).
We recruited children between 5 and 16 years old attending 6 rural and 3
urban schools. Approximately 35% (1714/4852) of all children attending
targeted schools agreed to participate in the study (see Fig E1 in this article’s
Online Repository at www.jacionline.org). The overall participation rate in the
rural schools was 34.7% comparedwith 36.4% in the urban schools. Therewas
no information available on nonparticipants. Of 1714 children enrolled, 59
subjects were ultimately unavailable for data collection, and 51 were excluded
for being outside of the age range (see Fig E2 in this article’s Online Repos-
itory at www.jacionline.org), leaving a total study population of 1604
children. Parameters measured were IgE serology (n5 1328), SPT reactivity
(n 5 1396), questionnaire results (n 5 1372), urinary schistosomiasis (n 5
1537), intestinal helminths (n 5 1398), and malaria blood films (n 5 1468).
Component-resolved diagnostics (CRD) could only be performed for a
maximum of 50 subjects because of budgetary limitations. Subjects for whom
a sufficient serum volume (>_350 mL) was available were included based on
reported adverse reactions to peanut (n 5 8), peanut SPT response positivity
(n5 15), and randomly selected subjects with IgE levels to peanut of greater
than 1.5 kU/L (n5 15). This threshold was chosen to increase the sensitivity
for measuring IgE levels against individual peanut allergens. Five randomly
selected negative control subjects with no reported adverse reactions to peanut
and no peanut sensitization were also included. The detailed selection
procedure for the CRD subset can be found in the Methods section in this
article’s Online Repository and also see Fig E3.Parasitological examinations
One stool sample per subject was collected for the detection of intestinal
helminth eggs by using theKato-Katz technique19 with 25mg of stool. A urine
sample was also collected to determine Schistosoma haematobium infectionby using the standard filtration method20 in which 10 mL of urine is filtered
through a nylon nucleopore filter (pore size, 12 mm). For each subject, a small
quantity of blood was collected to prepare a Giemsa-stained thick smear slide
to detect malaria.
Questionnaire
A standard questionnaire (for a copy of the questionnaire, see this article’s
Online Repository at www.jacionline.org) was administered to the parents or
guardians of study subjects to collect information on demographic and socio-
economic parameters, as well as information on established risk factors for the
development of allergy. Questions on the symptoms of adverse reactions to
food were included in the questionnaire. These were adapted from the vali-
dated EuroPrevall survey questionnaire.21 The questionnaire was adminis-
tered by trained interviewers who were fluent in the local language of each
participant. It was pretested in a pilot study under field conditions to ensure
understanding and acceptability.
SPTs
SPT reactivity to a commercially available whole peanut extract (kindly
provided by ALK-Abello, Madrid, Spain) was assessed by using the standard
protocol,22,23 as has been described in detail elsewhere.24 We defined peanut
SPT response positivity as a mean wheal diameter of 3 mm or greater.25
IgE antibody measurements
ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden) measurements
were carried out according to the manufacturer’s instructions. IgE levels to
peanut were assessed in all participants, and 0.35 kU/L was used as the
sensitization cutoff. A cutoff of 15 kU/L or greater, which is reported to have a
positive predictive value of 95% for clinical peanut allergy,26 was also
examined.
For the CRD subset (n5 43), specific IgE to recombinant peanut allergens
(rAra h 1, 2, 3, and 9), profilin (rPhl p 12), and bromelain, a marker for cross-
reactive carbohydrate determinants (CCDs), was assessed by using Immuno-
CAP. Bet v 1–homologous Ara h 8 was excluded from the analysis because
there is no exposure to Fagales tree pollen in Ghana.
IgE inhibition assays
Titrated ImmunoCAP inhibition assays were conducted to establish the
degree of cross-reactivity of peanut-specific IgE. To this end, 75 mL of pooled
serum comprised of equal volumes of 17 sera (all with peanut-specific IgE
levels >_5.5 kU/L and similar IgE responses to peanut, as well as to bromelain)
was mixed with 75 mL of inhibitor. Inhibitors used were either bromelain, S
haematobium soluble egg antigen (SEA), S haematobium adult worm antigen,
orAscaris lumbricoides antigen. For 3 subjects, 2 with high and 1with low IgE
titers to Ara h 9, individual sera were also tested by using ImmunoCAP inhi-
bition. Each serum pool (or individual sera) was preincubatedwith an inhibitor
at room temperature for 1 hour. Subsequently, samples were analyzed for
peanut-specific IgE, as described above. Results were expressed as percent-
ages of an uninhibited control (PBS).
Basophil histamine release assays
Basophil histamine release (BHR) assays were performed with stripped
basophils from a nonallergic donor that were sensitized with sera of subjects
selected from the CRD subset (n 5 43) to assess the biological activity of
peanut-specific IgE in our population. Two sera with similar IgE levels against
peanut and CCDs were selected. In addition, 2 sera with higher IgE levels
against peanut than against CCDs in combination with high IgE levels against
Ara h 9 were also evaluated (see full characteristics in Table E1 in this article’s
Online Repository at www.jacionline.org). BHR assays were performed, as
described elsewhere.27,28
Statistical analysis
Analysis was carried out with STATA version 10 software (StataCorp,
College Station, Tex). Urban-rural differences in subjects’ characteristics, as
TABLE I. Characteristics of the study population stratified by area
Factor
Area
P value*All, n/N (%) Rural, n/N (%) Urban, n/N (%)
Sex
Male 757/1604 (47.2) 465/976 (47.6) 292/628 (46.5) .65
Female 847/1604 (52.8) 511/976 (52.4) 336/628 (53.5)
Age
<_11 y 785/1604 (48.9) 496/976 (50.8) 289/628 (46.0) .06
>_11 y 819/1604 (51.1) 480/976 (49.2) 339/628 (54.0)
Parasitic infections
Any intestinal helminth (positive) 248/1398 (17.7) 236/834 (28.3) 12/564 (2.1) <.001
S haematobium (positive) 103/1537 (6.7) 83/922 (9.0) 20/615 (3.3) <.001
Plasmodium species (positive) 349/1468 (23.8) 310/880 (35.2) 39/588 (6.6) <.001
Peanut consumption
Daily (yes) 365/1372 (26.6) 316/874 (36.2) 49/498 (9.8) <.001
Weekly (yes) 760/1372 (55.4) 438/874 (50.1) 322/498 (64.7) <.001
Monthly (yes) 183/1372 (13.3) 70/874 (8.0) 113/498 (22.7) <.001
Every 6 mo (yes) 21/1372 (1.5) 12/874 (1.4) 9/498 (1.8) .52
Never (yes) 35/1372 (2.6) 35/874 (4.0) 0/498 (0.0) <.001
Missing consumption information 8/1372 (0.6) 3/874 (0.3) 5/498 (1.0)
Exclusive peanut preparation methods
Boiled only (yes) 61/1372 (4.4) 56/874 (6.4) 5/498 (1.0) <.001
Fried only (yes) 19/1372 (1.4) 19/874 (2.2) 0/498 (0.0) .001
Roasted only (yes) 277/1372 (20.2) 276/874 (31.6) 1/498 (0.2) <.001
Other peanut preparation methods
Raw (yes) 22/1372 (1.6) 3/874 (0.3) 19/498 (3.8) <.001
Peanut oil§
Use of peanut oil (yes) 33/1370 (2.4) 32/872 (3.7) 1/498 (0.2) <.001
*P values were calculated by using Pearson x2 test with 1 df. Values in boldface indicate significance.
Any intestinal helminth 5 Ascaris lumbricoides, hookworm (Ancylostoma duodenale or Necator americanus), Trichuris trichiura, or Schistosoma mansoni.
Plasmodium species 5 Plasmodium falciparum or Plasmodium malariae (the 2 malaria parasite species detected in our study population).
§Peanut oil use information missing for 2 participants.
TABLE II. Prevalence of adverse reactions to peanut and
peanut sensitization (SPT responses and IgE levels) stratified
by area
Factor
Area
P value*All, n/N (%) Rural, n/N (%)
Urban,
n/N (%)
Adverse reactions
to food
Any food 154/1372 (11.2) 115/874 (13.2) 39/498 (7.8) .003
Peanut 21/1372 (1.5) 18/874 (2.1) 3/498 (0.6) .035
SPT reactivity
Peanut positive 28/1396 (2.0) 17/881 (1.9) 11/515 (2.1) .79
Peanut-specific IgE
>_0.35 kU/L 233/1328 (17.5) 177/751 (23.6) 56/577 (9.7) <.001
>_15 kU/L 12/1328 (0.9) 8/751 (1.1) 4/577 (0.7) .48
*P values were calculated by using the Pearson x2 test with 1 df. Values in boldface
indicate significance.
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were examined by using the Pearson x2 test with 1 df. To assess factors asso-
ciated with peanut sensitization (IgE levels and SPT responses) and reported
adverse reactions, multivariable random effects logistic regression models
were fitted that took into account possible correlations among observations
within each school by modeling school as a random effect. This approach
was used because children attending the same school were likely to share com-
mon characteristics, as well as exposures. Models were adjusted for age, sex,
and urban-rural area (as a priori confounders) along with other variables sig-
nificant from crude analysis.
RESULTS
Characteristics of the study population
The characteristics of the study participants stratified by area
are given in Table I. There were no significant differences in
sex distribution and age group when comparing the 2 areas, al-
though urban children had a slightly higher median age. In addi-
tion, rural subjects had significantly more helminth infections and
malaria.
Although peanut consumption was high in both areas,
reported daily consumption was considerably higher among
rural schoolchildren (36.2%) compared with their urban coun-
terparts (9.8%). Furthermore, in the rural area both ‘‘boiled-
only’’ and ‘‘roasted-only’’ peanut preparation methods were
reported more frequently than in the urban area, where the
combination of roasting and then boiling peanuts in soup
preparation was more common. Topical exposure to peanut, as
assessed based on the use of peanut oil as a skin ointment, was
higher in rural compared with urban schools.Reported adverse reactions and sensitization (IgE
levels and SPT responses) to peanut
Adverse reactions were reported in 1.5% (n 5 21/1372) of
participants (Table II), most of whom were rural schoolchil-
dren. The distribution pattern of the characteristics of those re-
porting adverse reactions (see Table E2 in this article’s Online
Repository at www.jacionline.org) did not differ significantly
from the rest of the study population (statistical test data not
shown). About 67% of those reporting adverse reactions to pea-
nut had gastrointestinal complaints, and 43% had complaints
FIG 1. Overlap between reported adverse reactions to peanut and peanut sensitization (IgE levels and SPT
responses) for subjects with complete data for allergy-related parameters (n 5 1004).
TABLE III. Factors associated with reported adverse reactions to peanut and peanut sensitization (IgE levels and SPT responses)
Factors
Peanut-specific IgE
(>_0.35 kU/L vs <0.35 kU/L)
Positive peanut
SPT response (1 vs 2)
Reported adverse reactions to
peanut (yes vs no)
aOR (95% CI)
Wald test
P value aOR (95% CI)
Wald test
P value aOR (95% CI)
Wald test
P value
Peanut-specific IgE (>_0.35 kU/L vs <0.35 kU/L) 17.09 (6.30-46.36) <.001 1.94 (0.57-6.63) .29
Positive peanut SPT response (1 vs 2) 2.82 (0.35-22.70) .33
Age (>_11 y vs <11 y) 1.07 (0.78-1.47) .67 1.36 (0.55-3.36) .51 0.58 (0.24-1.42) .23
Sex (male vs female) 1.12 (0.83-1.51) .47 1.65 (0.67-4.03) .27 0.68 (0.28-1.65) .39
Area (urban vs rural) 0.41 (0.25-0.67) <.001 2.94 (1.03-8.40) .044 0.30 (0.09-1.01) .052
Any intestinal helminth* (1 vs 2) 1.01 (0.66-1.55) .97 0.69 (0.17-2.84) .61 0.35 (0.08-1.56) .17
S haematobium (1 vs 2) 2.29 (1.37-3.86) .002 0.41 (0.05-3.42) .41 0.65 (0.08-4.95) .67
Plasmodium species (1 vs 2) 1.10 (0.77-1.56) .61 0.49 (0.13-1.82) .28 0.59 (0.16-2.20) .44
Peanut-specific IgE models were adjusted for age, sex, area, and S haematobium infection. Peanut SPT models were adjusted for age, sex, area and peanut-specific IgE levels.
Reported peanut reaction models were adjusted for age, sex, and area.
*Any intestinal helminth 5 Ascaris lumbricoides, hookworm (Ancylostoma duodenale or Necator americanus), Trichuris trichiura, or Schistosoma mansoni.
Plasmodium species 5 Plasmodium falciparum or Plasmodium malariae (the 2 malaria parasite species detected in our study population).
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4 of 21 subjects reported a reaction time ‘‘within minutes’’
(see Table E3 in this article’s Online Repository at www.
jacionline.org).
The percentage of subjects with a positive peanut SPT response
was 2.0% (n 5 28/1396), and this was not significantly different
between the 2 areas (Table II). Positive wheal sizes for peanut
ranged from 3.0 to 6.5 mm and did not vary between areas
(data not shown).
Peanut IgE sensitization (>_0.35 kU/L) was observed in
17.5% (n 5 233/1328) of the study population, with 23.6% of
rural children being sensitized compared with 9.7% of urban
participants (P < .001). However, 92.4% (n 5 194/210) of
those IgE sensitized to peanut (>_0.35 kU/L) had negative pea-
nut SPT responses. Interestingly, 0.9% (n 5 12/1328) of the
study subjects were highly sensitized when using the IgE cut-
off of 15 kU/L or greater, which is reported to have a positive
predictive value of 95% for clinical peanut allergy,26 but only
1 of them reported reactions. Fig 1 shows the overlap between
the peanut-related outcomes for study subjects with complete
allergy data (reported reactions, SPT levels, and IgEresponses). No subjects had positive results for all 3
parameters.Factors associated with peanut sensitization (IgE
levels and SPT responses) and reported adverse
reactions to peanut
In multivariable analysis area was strongly associated with
peanut IgE sensitization of 0.35 kU/L or greater, with urban
subjects having a reduced odds of increased IgE levels relative to
their rural counterparts (adjusted odds ratio [aOR], 0.41; 95% CI,
0.25-0.67; P < .001; Table III). S haematobium infection was also
associatedwith peanut IgE sensitization (aOR, 2.29; 95%CI, 1.37-
3.86; P5 .002), whereas intestinal helminth infection was not.
Although themajority of peanut IgE–sensitized subjects did not
have positive peanut SPT responses, almost all subjects with
positive peanut SPT responses were IgE sensitized. Thus in
multivariable analysis IgE sensitization was associated with
peanut SPT reactivity (aOR, 17.09; 95% CI, 6.30-46.36;
P <.001). In addition, although not observed in crude analyses, re-
siding in an urban area was associated with a significantly higher
FIG 2. A,Measurement of specific IgE levels towhole peanut extract, recombinant peanut allergens, profilin,
and the CCD marker bromelain in a subset (n 5 43). Median specific IgE levels are indicated by black lines.
The dotted line shows an IgE sensitization cutoff of 0.35 kU/L.B,Correlation between peanut-specific IgE and
CCD-specific IgE levels. Open circles indicate subjects with IgE to rAra h 9 of greater than 1.5 kU/L.
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for confounders (Table III). No other factors, including helminth
infection, had an effect on SPT responses to peanut (Table III).
Data on peanut consumption and preparation methods as risk
factors for peanut-related outcomes are shown in Table E4 in this
article’s Online Repository at www.jacionline.org. ‘‘Never’’ con-
suming peanuts, as a proxy for avoidance, was associated with re-
ported symptoms (aOR, 5.40; 95% CI, 1.47-19.80; P < .05). Raw
peanut consumption was also linked to reported adverse reactions
to peanut (aOR, 17.14; 95% CI, 2.93-100.45; P < .01). However,
numbers were low, as reflected in the wide CI. All other factors,
including helminth infection, were not significantly associated
with reported adverse reactions to peanut (Table III and see
Table E4).Component-resolved IgE testing
Fig 2, A, shows the results of CRD performed in a subset (n5
43) to better characterize peanut-specific IgE. Those with IgElevels to peanut of greater than 1.5 kU/L (median, 12.5 kU/L)
had high levels of IgE to CCD but low IgE responses (<1.3 kU/
L) to rAra h 1 to 3 and rPhl p 12. A strong correlation was seen
between peanut-specific IgE and CCD-specific IgE levels (r 5
0.89, P < .0001; Fig 2, B). For some subjects, IgE levels against
peanut were significantly higher than those to CCDs, and in 6
of these subjects, high titers of IgE to the lipid transfer protein
rAra h 9 were observed (Fig 2, A). Of note, 4 of 6 of these subjects
had positive peanut SPT responses (see Table E1).Inhibition of IgE binding to peanut by CCDs and
schistosome egg antigen
Titrated CAP inhibition assays demonstrated that binding of
IgE from a serum pool of subjects (n5 17) with similar IgE titers
to peanut as to CCDs was almost completely inhibited by CCDs,
as well as by S haematobium SEA (Fig 3). Interestingly, SEA, a
glycoprotein preparation of S haematobium eggs, inhibited at a
greater than 100-fold lower protein concentration than the
FIG 3. Inhibition of IgE binding to whole peanut by bromelain and S haematobium SEA by using pooled
sera (n 5 17). The figure shows that IgE binding to whole peanut extract was almost completely inhibited
by bromelain (diamonds) and S haematobium SEA (triangles), respectively.
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ual inhibitions for 2 subjects with high IgE levels to peanut and
Ara h 9, as well as low IgE levels to CCDs, showed less than
10% inhibition by SEA (see Table E1). In addition, S haema-
tobium adult worm antigen and A lumbricoides antigen did not in-
hibit binding significantly (data not shown).
BHR assays
Peanut extract induced little histamine release when basophils
were sensitized with IgE from subjects with similar IgE reactivity
to peanut as to CCDs (Fig 4, A and B). For these subjects, the abil-
ity of S haematobium SEA to induce histamine release was tested,
and only at a concentration of 10 mg/mL was release observed.
For 2 subjects with titers of IgE against Ara h 9 of greater than
70 kU/L (Fig 4, C and D), Ara h 9 induced significant histamine
release starting at 10 pg/mL, reaching maximum release at ap-
proximately 1 ng/mL, whereas with peanut extract, release was
seen starting from a concentration of 10 mg/mL.
DISCUSSION
Our study is the first investigation of reported adverse reactions
to peanut and peanut sensitization based on serum specific IgE
measurements, as well as SPT reactivity, in Sub-Saharan Africa
among an unselected group of children. We confirmed that there
was a high frequency of daily peanut consumption in Southern
Ghana, particularly among rural schoolchildren. We also ob-
served an association between reported peanut-related adverse
reactions and peanut avoidance. The percentage of reported
peanut-related adverse reactions among schoolchildren in our
survey was 1.5%. However, the majority of these reported
reactions occurred within hours/days, whereas IgE-mediated
peanut allergy is typically associated with symptoms appearing
within minutes or up to 2 hours.29
Among study participants, 2.0% had positive peanut SPT
responses. Although 17.5% of all subjects had increased IgElevels to peanut (>_0.35 kU/L), 92.4% of these had negative peanut
SPT responses. One explanation for the discrepancy between
specific IgE levels and SPT responses could be the suppression of
IgE-induced inflammation by immunologic regulatory net-
works30 that might be operative during chronic helminth infec-
tions. However, we did not observe any association between
helminth infection and SPT responses to peanut.
Notably, 12 of 1328 participants had peanut-specific IgE levels
of 15 kU/L or greater, a cutoff reported to have a positive
predictive value of 95% for clinical peanut allergy in a European
study population26 but was virtually unaccompanied by reported
symptoms in our study. This highlights the limitations in applying
cutoff values determined in one population to other populations.
Analysis by CRD in a subset indicated that the majority of
those with high IgE titers against peanut (median, 12.5 kU/L) had
low responses (<1.3 kU/L) against the major peanut allergens
(Ara h 1, 2, and 3) commonly associated with peanut allergy.31-33
Recently, IgE responses to Ara h 2 in particular have been used to
differentiate between clinical peanut allergy and asymptomatic
peanut sensitization,34 as well as to improve diagnostic accur-
acy.35 One study observed that an IgE cutoff to rAra h 2 of greater
than 0.23 kU/L had a specificity of 97% and sensitivity of 93%
among patients with peanut allergy and control subjects in
France.32 Taken together, sensitization to peanut storage proteins
in Ghana appears weak and rare compared with that in European
or US patients with peanut allergy. The lack of clinical reactivity
among study participants with increased IgE responses to Ara h 2
would have to be explored further.
The most dominant molecular component recognized by IgE in
peanut-sensitized subjects in our subset was the CCD. A strong
correlation was observed between IgE levels to peanut and to
CCDs. CCDs are N-glycans in plants and invertebrate glycopro-
teins that result in a high degree of cross-reactivity between pollen
and foods.36 CCDs have negligible in vivo biological activity, as
well as clinical relevance.37-39 Grass pollenwas found to be ofmi-
nor importance in Ghanaian schoolchildren, as was established in
FIG 4. BHR assay results. BHR induced by peanut extract (solid circles), S haematobium SEA (open trian-
gles), and Ara h 9 (open circles). A and B, Results for 2 subjects with high IgE titers against peanut and
CCD. C and D, Results for 2 subjects with high IgE titers against peanut and Ara h 9 but low IgE titers against
CCDs.
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we observed that current S haematobium infection was associated
with increased IgE levels to peanut. Moreover, among our subset,
the results of the ImmunoCAP inhibition assays showed that
plant-derived CCDs (bromelain) inhibited IgE binding to peanut
but that a Schistosoma species–derived glycoprotein was a far
more potent inhibitor. These observations suggest that
carbohydrate-specific IgE is induced by glycoproteins from the
eggs of S haematobium that are different from but cross-
reactive with those on bromelain. Interestingly, Schistosoma
species adult worm glycoproteins were not effective as inhibitors,
indicating the importance of stage-specific N-glycans in this
cross-reactivity. The importance of cross-reactivitymight also ex-
plain the residual effect of the rural area on IgE to peanut, which
was seen after adjusting for current S haematobium infection. Past
infections in subjects residing in the rural area might have led to
cross-reactive IgE to peanut.
Interestingly, in the studied subset IgE responses to Ara h 9
were increased in 6 children, with 2 having IgE titers of greaterthan 70 kU/L. Furthermore, IgE antibodies against Ara h 9 were
biologically active at low allergen concentrations (picogram per
nanogram range), as determined by using BHR assays. The
observation that 4 of 6 subjects with high IgE levels to Ara h 9 had
positive peanut SPT responses is in line with these BHR results.
However, none of these reported immediate adverse reactions to
peanut. Altogether, the data suggest that sources other than CCDs
could contribute to increased IgE levels to peanut extract. The
origin of sensitization to this lipid transfer protein is unknown,
and whether a locally consumed fruit is at the basis of this
sensitization, as is commonly reported in Europe in relation to
peach,31,40,41 remains to be determined for Ghana.
Our study had a number of limitations, such as a low partic-
ipation rate, but given our observation that IgE-mediated peanut
allergy in Ghanaian schoolchildren is rare (if existing at all), it is
unlikely that selection bias is affecting our findings in this respect.
However, the borderline significant difference in age between
rural and urban children, as well as the fact that the rural
population is from areas that are endemic for helminth infections,
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ability of our findings. The absence of a gold standard for peanut
allergy (oral food challenges) is another limitation, but given that
reported adverse reactions to peanut were largely not accompa-
nied by immediate reactions, this is less likely to be an issue. An
additional study weakness is the use of a questionnaire as a
measurement tool for adverse reactions, as well as other self-
reported parameters. Furthermore, our school-based study design
meant that children less than 5 years of age were excluded from
the investigation, which might bias the results by omitting an
important age group affected by peanut allergy. However, given
the persistent nature of peanut allergy among most subjects, the
effect of an older age cutoff of 5 years is likely to be minimal. The
fact that CRD was conducted in a relatively small subset of our
larger study population is another limitation, although the subset
did not differ from the wider study population on key demo-
graphic factors and parasitic infections.
Despite these limitations, our study provides new insight into
the nature of peanut sensitization and reported adverse reactions
to peanut in Ghana, a Sub-Saharan African country in which
peanut consumption is high but does not appear to translate into
true peanut sensitization, let alone peanut allergy. Overall, our
observations suggest that IgE-mediated peanut allergy in Gha-
naian schoolchildren is rare. Among a subset, we found a role for
N-glycans, particularly related to Schistosoma species, in induc-
ing cross-reactivity, resulting in increased IgE levels to peanut
without skin reactivity or reported symptoms. This study once
more highlights the poor biological activity of CCD-specific
IgE. Interestingly, IgE to Ara h 9 demonstrated normal biological
activity, suggesting that lack of biological activity is not the only
explanation for the lack of clinical peanut allergy. Future studies
on the characteristics of cross-reactive IgEs and the pathways be-
hind their development might be essential to the ongoing investi-
gation of immune regulatory mechanisms in an effort to curtail
strong allergic inflammation.
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Clinical implications: Peanut-specific IgE antibodies in Ghana,
a Sub-Saharan African country, show cross-reactivity with clin-
ically irrelevant carbohydrate determinants and therefore
might reduce the diagnostic value of this parameter in establish-
ing peanut allergy.
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